Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04560361
Other study ID # 2020NL-103-02
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 14, 2020
Est. completion date October 30, 2023

Study information

Verified date March 2023
Source Nanjing University of Traditional Chinese Medicine
Contact Jianhua Sun
Phone +86 25-86617141-31300
Email 377201634@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators designed the multicenter randomized parallel controlled clinical trial of electroacupuncture on PHN which is rigorously designed and have an appropriate sample size, aiming to evaluate the efficacy and safety of electroacupuncture in pain relieving and pain removing in the treatment of patients with PHN.


Description:

Postherpetic neuralgia(PHN) is the most common complication of herpes zoster, is a severe and intractable pain with a high incidence. Nearly 50% of PHN patients have experienced persistent pain for more than one year. Although it is not directly life-threatening, will lead to sleep disorders, even depression, seriously affecting the quality of life of patients. This project is a multi-center randomized controlled trial, which will recruit 448 patients with PHN in 7 hospitals, aiming to evaluate the analgesic effect and safety of electroacupuncture on postherpetic neuralgia, and provide evidence-based medical evidence for electroacupuncture treatment of PHN.


Recruitment information / eligibility

Status Recruiting
Enrollment 448
Est. completion date October 30, 2023
Est. primary completion date July 20, 2022
Accepts healthy volunteers No
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: - Patients who meet the diagnostic criteria for postherpetic neuralgia (with a clear history of acute herpes zoster, and the duration of postherpetic pain exceeds 90 days) - Aged 45 to 75 years old - Patients who were diagnosed with moderate or above pain during the observation period (the daily pain score was continuously collected within 7 days during the observation period, and the average NRS-11 pain score was >=4) - Subjects who did not participate in other ongoing clinical studies - Sign informed consent and volunteer to participate in the study Exclusion Criteria: - Patients who are currently receiving or receiving more than one of the "permitted combinations" or any "prohibited combination and treatment" for PHN listed in the following part at least 14 days before screening, and are unwilling to undergo washout period, or patients with serious safety problems during washout period or observation period - Patients who are expected to receive any new prescription drug or other treatment for PHN after the start of the trial - Patients with serious uncontrolled medical conditions, such as cardiovascular, lung, liver, kidney, gastrointestinal tract, metabolism, endocrine, nervous system, respiratory system, urogenital system and other serious diseases, or systemic organ dysfunction, malignant tumor, hematologic disease such as bleeding tendency or coagulation dysfunction, serious mental illness such as depression or schizophrenia Symptoms, hepatitis B antigen or hepatitis C antibody positive known state or history of immune dysfunction, history of HIV infection, etc. - Patients with severe pain unrelated to PHN, such as after surgery for clinical major diseases - Patients with PHN who have received nerve intervention or other neurosurgical treatment, such as selective nerve damage, percutaneous radiofrequency thermocoagulation or pulsed nerve modulation technology, etc. - Patients with some special types of herpes zoster, such as those with meninges, cornea, conjunctiva, ear involvement, visceral herpes zoster, generalized herpes zoster - Patients with skin ulceration, new herpes, or skin infection - Patients with cardiac pacemaker, metal allergy or severe fear of needle - Patients who are unable to give full informed consent or cannot cooperate with pain scale assessment due to mental, mental, linguistic or behavioral disorders - Patients who have poor compliance or are prone to fall off due to other reasons, such as the current residence is not in the city where the recruitment hospital is located, or the working environment changes frequently - Pregnant and lactating women

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Electroacupuncture treatment
Continue the electroacupuncture treatment as described above for 30 minutes.
Sham electroacupuncture treatment
Continue the sham electroacupuncture treatment as described above for 30 minutes.

Locations

Country Name City State
China Huai'an Hospital of Traditional Chinese Medicine Huai'an Jiangsu
China Lianyungang Hospital of Traditional Chinese Medicine Lianyungang Jiangsu
China Jiangsu Province Hospital of Chinese Medicine Nanjing Jiangsu
China Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine Nanjing Jiangsu
China Nantong Hospital of Traditional Chinese Medicine Nantong Jiangsu
China Shuyang Hospital of Traditional Chinese Medicine Suqian Jiangsu
China Wuxi Hospital of Traditional Chinese Medicine Wuxi Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Nanjing University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

References & Publications (7)

Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S; European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011 Jun;41(6):1073-93. doi: 10.1016/j.jpainsymman.2010.08.016. — View Citation

Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014 Jun 10;4(6):e004833. doi: 10.1136/bmjopen-2014-004833. — View Citation

Pei W, Zeng J, Lu L, Lin G, Ruan J. Is acupuncture an effective postherpetic neuralgia treatment? A systematic review and meta-analysis. J Pain Res. 2019 Jul 16;12:2155-2165. doi: 10.2147/JPR.S199950. eCollection 2019. — View Citation

van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014 Apr;155(4):654-662. doi: 10.1016/j.pain.2013.11.013. Epub 2013 Nov 26. Erratum In: Pain. 2014 Sep;155(9):1907. — View Citation

Wang L, Qiu L, Zheng X, Ouyang J, Zhang M, He L, Zeng S, Liu B, Peng J. Effectiveness of electroacupuncture at Jiaji acupoints (EX-B2), plus moxibustion and intermediate on postherpetic neuralgia: a randomized controlled trial. J Tradit Chin Med. 2020 Feb;40(1):121-127. — View Citation

Werner RN, Nikkels AF, Marinovic B, Schafer M, Czarnecka-Operacz M, Agius AM, Bata-Csorgo Z, Breuer J, Girolomoni G, Gross GE, Langan S, Lapid-Gortzak R, Lesser TH, Pleyer U, Sellner J, Verjans GM, Wutzler P, Dressler C, Erdmann R, Rosumeck S, Nast A. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):9-19. doi: 10.1111/jdv.13995. Epub 2016 Nov 2. — View Citation

Wu CH, Lv ZT, Zhao Y, Gao Y, Li JQ, Gao F, Meng XF, Tian B, Shi J, Pan HL, Li M. Electroacupuncture improves thermal and mechanical sensitivities in a rat model of postherpetic neuralgia. Mol Pain. 2013 Apr 3;9:18. doi: 10.1186/1744-8069-9-18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in pain intensity (NRS-11) 11-point numeric rating scale (NRS-11): range from 0 (no pain) to 10 (worst possible pain), with 1-3 points representing mild pain, 4-6 points representing moderate pain, and 7-10 points representing severe pain. A reduction of =30% in NRS-11 scores from baseline were considered responders. Change from Baseline at 4 weeks after treatment
Secondary Change in pain intensity (VAS) Visual analogue scale (VAS): a horizontal line without verbal descriptors or numbers at intermediate points (0=no pain, 10=worst imaginable pain) Change from Baseline at 1 day, 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after treatment
Secondary Change in the interference of pain on sleep Verbal rating scale (VRS): 4 levels.
Level 0: No pain.
Level I (mild): Pain but tolerable, normal life, no interference with sleep.
Level II (moderate): Pain is obvious, unbearable, requires analgesic medication, and sleep is disturbed.
Level III: Severe pain, unbearable, analgesic medication, severe interference with sleep, accompanied by autonomic dysfunction or passive positions.
Change from Baseline at 1 day, 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after treatment
Secondary Change in mechanical pain threshold (MPT) Stimulated the most painful central part of PHN with a series of von Frey hairs (0.008-300 g). Change from Baseline at 1 day, 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after treatment
Secondary Change in pain area of PHN (PAP) calculated by the researcher based on 45 body areas rating scale (BARS-45) which requires the use of height and weight of the patient. Change from Baseline at 1 day, 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after treatment
Secondary Change in average number of pain episodes per day Painless: 0 times; Intermittent pain: 1-50 times (1-2, 3-5, 6-10, 11-50 optional); Persistent pain: >50 times. Change from Baseline at 1 day, 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after treatment
Secondary Change in average duration of each pain episode (ADEPE) Duration ranges from 0 minutes (no pain) to 24 hours (persistent pain). Change from Baseline at 1 day, 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after treatment
Secondary Change in the nature and intensity of pain short form of McGill pain questionnaire 2 (SF-MPQ-2): includes 22 items. Change from Baseline at 4 weeks after treatment
Secondary Change in degree of pain and its impact on work life, interpersonal relationships and sleep Zoster brief pain inventory (ZBPI) Change from Baseline at 4 weeks after treatment
Secondary Change in depression, anxiety and positive outlook scale (DAPOS) 11 items, combines depression (5 items), anxiety (3 items) and positive outlook (3 items). Change from Baseline at 4 weeks after treatment
Secondary Change in overall impression of PHN Patient global impression of change (PGIC): Participants were asked to describe their overall impression of change of their condition/pain by answering the following question: "Compared to your pain at admission to the project, how much has it changed?" (categories: much improved = 1, mildly improved = 2, unchanged = 3, mildly worsened = 4, much worsened = 5). 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT04546334 - Erector Spinae Plane Block in Post-herpetic Neuralgia N/A
Terminated NCT01744522 - Leech Therapy for Postherpetic Neuralgia N/A
Completed NCT01688947 - Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00566904 - New Topical Treatment for Continued Pain After Shingles Phase 1
Completed NCT00478179 - Study of a Bupivacaine Patch (Eladurâ„¢) to Treat Post- Herpetic Neuralgia Phase 2
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Terminated NCT01603394 - Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia Phase 4
Completed NCT01228838 - Study of NGX-1998 for the Treatment of Postherpetic Neuralgia Phase 2
Completed NCT01251211 - Botulinum Toxin in Peripheral Neuropathic Pain Phase 4
Completed NCT00612105 - Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN) Phase 2
Recruiting NCT05568186 - Correlation Between Thermal Patterns of Infrared Thermal Imaging and Clinical Phenotype in Patients With Postherpetic Neuralgia
Recruiting NCT04664530 - The Study on the Esketamine in the Treatment of Postherpetic Neuralgia Phase 4
Active, not recruiting NCT01508676 - Effects of Pennsaid on Clinical Neuropathic Pain N/A
Completed NCT00885586 - Acupuncture in Herpes Zoster Neuralgia (ACUZoster) Phase 4
Completed NCT00981227 - Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia Phase 2
Completed NCT00576108 - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00238511 - An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00007501 - Shingles Prevention Study Phase 3
Completed NCT04594226 - Electroacupuncture Therapy for Treating Postherpetic Neuralgia N/A
Completed NCT05140863 - To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia Phase 3